Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
Tag: Remibrutinib
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]
Merck and Mayo Clinic launch AI-driven precision medicine partnership Merck and Mayo Clinic have officially kicked off a landmark R&D ...
#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation ...
